logo

For the Inventor, By the Inventor

Wayne, NJ, United States of America

Linda L Chang

USPTO Granted Patents = 22 

 

Average Co-Inventor Count = 3.7

ph-index = 10

Forward Citations = 298(Granted Patents)


Company Filing History:

goldMedal20 out of 4,770 
 
Merck + Co., Inc.
 patents
silverMedal2 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
bronzeMedal1 out of 212 
 
Merck Frosst Canada, Inc.
 patents
where one patent can have more than one assignee

Years Active: 1993-2012

Loading Chart...
Loading Chart...
22 patents (USPTO):Explore Patents
1. 8153626 - Substituted diazepine sulfonamides as bombesin receptor subtype-3 modulators (2012-04-10),
2. 7816534 - Substituted amides (2010-10-19),
3. 7629467 - Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use (2009-12-08),
4. 7550489 - Substituted pyridyoxy amides (2009-06-23),
5. 6972295 - Substituted amides (2005-12-06),
6. 6943180 - Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors (2005-09-13),
7. 6855708 - N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors (2005-02-15),
8. 6559174 - N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors (2003-05-06),
9. 6420418 - Heterocycle amides as cell adhesion inhibitors (2002-07-16),
10. 6271252 - Cyclic amino acid derivatives as cell adhesion inhibitors (2001-08-07),
11. 6090841 - Substituted pyrrole derivatives as cell adhesion inhibitors (2000-07-18),
12. 5955480 - Triaryl substituted imidazoles, compositions containing such compounds (1999-09-21),
13. 5880139 - Triaryl substituted imidazoles as glucagon antagonists (1999-03-09),
14. 5776954 - Substituted pyridyl pyrroles, compositions containing such compounds and (1998-07-07),
15. 5559135 - Endothelin antagonists bearing pyridyl amides (1996-09-24),

Title: Linda L. Chang: A Pioneering Inventor in Pharmaceutical Innovations

Introduction: Linda L. Chang, based in Wayne, NJ, is a distinguished inventor with an impressive portfolio of 22 patents. Her work focuses on innovative compounds that address various medical conditions, demonstrating her commitment to advancing pharmaceutical science and improving patient outcomes.

Latest Patents: Chang's latest contributions to the field include notable patents for novel compounds such as substituted diazepine sulfonamides, which serve as modulators for the human bombesin receptor subtype-3 (BRS-3). These compounds are particularly useful for treating and preventing disorders responsive to BRS-3 modulation, including obesity and diabetes. Additionally, she has developed substituted amides that act as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor. These innovative compounds have the potential to treat a wide array of medical issues, from psychosis and cognitive disorders to weight management and substance abuse disorders.

Career Highlights: Throughout her career, Linda L. Chang has made significant strides in the pharmaceutical industry while working at renowned companies including Merck & Company, Inc. and Merck Sharp & Dohme Corporation. Her dedication to research and development has led to impactful advancements in medications that address severe health challenges.

Collaborations: Chang has collaborated with esteemed colleagues, such as William K. Hagmann and Wallace T. Ashton. Their collective expertise and innovative ideas have undoubtedly contributed to the success and effectiveness of the patented compounds developed by Chang.

Conclusion: Linda L. Chang stands as a testament to the power of innovation in the pharmaceutical sector. With her extensive background and groundbreaking patents, she continues to make a profound impact on the treatment of various diseases. Her work reflects the importance of perseverance and creativity in the quest for medical advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…